Drapkin R - Search Results

1

Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen.

Drapkin R, Di Bella NJ, Faragher DC, Harden E, Matei C, Hyman W, Mirabel M, Boehm KA, Asmar L. Drapkin R, et al. Clin Lymphoma. 2003 Dec;4(3):169-75. doi: 10.3816/clm.2003.n.026. Clin Lymphoma. 2003. PMID: 14715099 Clinical Trial.

2

Pentostatin and rituximab in the treatment of patients with B-cell malignancies.

Drapkin R. Drapkin R. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):25-9. Oncology (Williston Park). 2000. PMID: 10887641

3

Infectious complications of pentostatin therapy.

Vose JM, Cabanillas F, O'Brien S, Dang N, Drapkin R, Foss F. Vose JM, et al. Among authors: drapkin r. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):41-2. Oncology (Williston Park). 2000. PMID: 10887644 Free article.

4

Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.

Weaver CH, Schwartzberg LS, Birch R, Greco FA, Hainsworth J, Drapkin R, Campos L, Grapski R, Schwerkoske J, Lautersztain J, Hazelton B, Schnell F, Babcock W, Buckner CD. Weaver CH, et al. Among authors: drapkin r. Biol Blood Marrow Transplant. 1997 Jun;3(2):83-90. Biol Blood Marrow Transplant. 1997. PMID: 9267668 Clinical Trial.

5

Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content.

Weaver CH, Potz J, Redmond J, Tauer K, Schwartzberg LS, Kaywin P, Drapkin R, Grant B, Unger P, Allen C, Longin K, Zhen B, Hazelton B, Buckner CD. Weaver CH, et al. Among authors: drapkin r. Bone Marrow Transplant. 1997 Jun;19(11):1103-10. doi: 10.1038/sj.bmt.1700808. Bone Marrow Transplant. 1997. PMID: 9193753

6

Effect of granisetron on performance status during high-dose interferon therapy.

Drapkin R, Barolo JL, Blower PR. Drapkin R, et al. Oncology. 1999 Nov;57(4):303-5. doi: 10.1159/000012065. Oncology. 1999. PMID: 10575316

7

Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells.

Reavis HD, Gysler SM, McKenney GB, Knarr M, Lusk HJ, Rawat P, Rendulich HS, Mitchell MA, Berger DS, Moon JS, Ryu S, Mainigi M, Iwanicki MP, Hoon DS, Sanchez LM, Drapkin R. Reavis HD, et al. Among authors: drapkin r. JCI Insight. 2024 Mar 8;9(5):e170961. doi: 10.1172/jci.insight.170961. JCI Insight. 2024. PMID: 38271085 Free PMC article.

8

Aneuploidy Landscape in Precursors of Ovarian Cancer.

Wang Y, Douville C, Chien YW, Wang BG, Chen CL, Pinto A, Smith SA, Drapkin R, Chui MH, Numan T, Vang R, Papadopoulos N, Wang TL, Shih IM. Wang Y, et al. Among authors: drapkin r. Clin Cancer Res. 2024 Feb 1;30(3):600-615. doi: 10.1158/1078-0432.CCR-23-0932. Clin Cancer Res. 2024. PMID: 38048050

9

MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer.

Bustos MA, Yokoe T, Shoji Y, Kobayashi Y, Mizuno S, Murakami T, Zhang X, Sekhar SC, Kim S, Ryu S, Knarr M, Vasilev SA, DiFeo A, Drapkin R, Hoon DSB. Bustos MA, et al. Among authors: drapkin r. Cell Biosci. 2023 Nov 6;13(1):200. doi: 10.1186/s13578-023-01151-y. Cell Biosci. 2023. PMID: 37932806 Free PMC article.

10

Performance of computational algorithms to deconvolve heterogeneous bulk ovarian tumor tissue depends on experimental factors.

Hippen AA, Omran DK, Weber LM, Jung E, Drapkin R, Doherty JA, Hicks SC, Greene CS. Hippen AA, et al. Among authors: drapkin r. Genome Biol. 2023 Oct 20;24(1):239. doi: 10.1186/s13059-023-03077-7. Genome Biol. 2023. PMID: 37864274 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

254 results

Search Page